The excellent anti-tumor effect shows that ISP-I provide a new therapeutic option targeting to NSCLC patients carrying KEAP1 mutation through excessive ROS accumulation and play dual roles as a PI3K/AKT pathway inhibitor simultaneously. Here, KEAP1 is linked to non-small cell lung carcinoma.